The main aim for drug discovery specialist ImmuPharma (LON:IMM) in 2012 are to advance its Lupuzor drug and its cancer treatment programme.
So said chief executive officer Dimitri Dimitriou at the firm's AGM earlier today.
He told shareholders 2011 had been an important year - where the firm had regained the rights to the lead compound Lupuzor, for the treatment of lupus.
Now the drug has approval from the US Food and Drug Administration to start a Phase III trial, along with obtaining fast track designation potentially shortening the approval time by a year.
The company is also in detailed discussions with potential partners to re-licence the drug, while also exploring opportunities to retaining the rights until commercialisation, Dimitriou told shareholders.
"Our cancer programme, IPP-204106, has also made encouraging progress with promising early results in its Phase I/IIa trial," he said.
"The trial is now completed and the data are being analysed and as previously announced 21 per cent of patients demonstrated disease stabilisation for more than 6 months.
"The clinical development programme continues to be a key priority for ImmuPharma during 2012 with further clinical trials planned this year."
The CEO added: "Our key objectives for 2012 are to advance both LupuzorTM and our cancer programme and to continue to develop the rest of our asset base whilst continuing to carefully manage our cost base."